HC Wainwright Reiterates “Buy” Rating for Daré Bioscience (NASDAQ:DARE)
Daré Bioscience (NASDAQ:DARE – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 312.37% from the stock’s current price. […]
Daré Bioscience (NASDAQ:DARE – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 312.37% from the stock’s current price. […]
